[1] |
JIANG Lu, ZHANG Zhidong, WU Jianjun, LIU Lu, SHANG Longjian, WEI Xingmin .
Changing trends in the disease burden of liver cancer in China and the United States from 1990 to 2021 and its predictions
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 55-60.
|
[2] |
WANG Haodi, DENG Zhengming, WANG Gang, JIANG Zhiwei.
Disease burden in colorectal cancer attributed to fasting hyperglycemia in china from 1990 to 2021 and projections of future trends
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 61-67.
|
[3] |
CAO Le, MA Minmin, LI Wenmin, SHUI Mingming, JIANG Cheng.
Trend of mortality and disease burden of gastric cancer in China,2004—2021
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 68-73.
|
[4] |
TAN Xiaoning, ZHANG Tianwen, LIU Bin, ZHAO Chang.
Clinical application value of preoperative interventional embolization in total en-bloc spondylectomy for spinal tumors
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 88-94.
|
[5] |
YANG Jun, KANG Wei, ZHONG Wuning, ZHAO Xin.
Predictive value of radiomics model based on cone-beam breast CT images for pathological complete response of neoadjuvant therapy in breast cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 103-108.
|
[6] |
ZHANG Yuanfen, LONG Ying, YAO Desheng.
Relationship between perineural invasion,clinical pathological characteristics of cervical cancer and its effects on prognosis
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 109-114.
|
[7] |
GUO Zhiyu, CAO Tianyu, WANG Weidong, GUO Xingxian, MA Wanqi, LU Yuanyuan, ZHAO Xiaodi, JI Gang.
Correlation between blood lipid levels and survival prognosis of gastric cancer patients under operation: A retrospective cohort study
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 687-693.
|
[8] |
WU Jialu, GE Xia, CHEN Wenming, YANG Guangzhong.
Current status and progress of CAR-T cell therapy in multiple myeloma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 525-531.
|
[9] |
LIU Jingqian, ZHANG Yajing.
Strategies for prevention,control and management of CAR-T cell therapy related adverse reactions
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 540-548.
|
[10] |
WANG Huijuan, CHEN Wenming, GENG Chuanying, YANG Guangzhong .
Clinical characteristics of patients with relapsed/refractory multiple myeloma after CAR-T cell therapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 549-553.
|
[11] |
SUN Yifei, GAO Wen, JIA Junlei, ZHANG Huilai, YU Jingwei, WANG Xianhuo.
Safety of CD19 CAR-T therapy: Signal mining and analysis of adverse events based on FAERS database
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 554-561.
|
[12] |
LYU Liwei, CONG Jia, WU Yiping, WANG Liang .
BCMA CAR-T cell therapy for relapsed/refractory plasmablastic lymphoma: case report and clinical implication
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 562-565.
|
[13] |
HE Ying, LI Mengjiao, CEN Yali, DOU Baitao, SHU Rou, LI Yanling, YAO Hao, FAN Fangyi.
CD19 CAR T-cell therapy: a case of refractory primary central nervous system diffuse large B-cell lymphoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 571-576.
|
[14] |
WANG Xingchen, LIAO Dawen, LI Jiaying, SUN Xiacheng, BI Qian, Huang Qichao, HUANG Jiangtao.
Comparative analysis of molecular characteristics of constitutive activation of NRAS and CTNNB1 in liver cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 577-585.
|
[15] |
XIAO Xiaoyinan, WANG Ruikun, HAN Meng, LIU Sihan, ZHUO Fangqi, CHEN Minkuan, DU Yimeng, CHE Yongsheng, XU Xiaojie.
Construction of recombinant plasmid of AGK gene promoter and its transcriptional activity in T lymphocyte leukemia
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 586-592.
|